Evicenter
MarkdownMedical informationP&T meetings

VK2735

Chronic weight management

Last updated
184 sources

Section 2 of 6

Executive summary

8 evidence topics · 60 sources

Clinical benefits of VK2735

Burden of Chronic weight management

Summary: definition, epidemiology, mortality, and morbidity

The World Health Organization defines overweight in adults as a body mass index (BMI) of 25 or greater and obesity as a BMI of 30 or greater, and its 2026 guideline describes obesity as “a chronic, relapsing disease”. The Lancet Diabetes and Endocrinology Commission defines clinical obesity as “a chronic, systemic illness” caused by excess adiposity and preclinical obesity as excess adiposity with preserved organ function and an increased risk of progression. Causes are multifactorial, and family, twin, and adoption studies attribute at least 40% to 70% of the variation in body weight to genetic factors.

In measured data for U.S. adults from August 2021 to August 2023 (NCHS Data Brief), the prevalence of obesity was 40.3% (39.2% in men, 41.3% in women), highest at ages 40 to 59 years (46.4%), and the prevalence of severe obesity was 9.4%; a further 32.1% of adults were overweight (unadjusted). From 2013 to 2014 through 2021 to 2023, age-adjusted obesity prevalence did not change significantly, while age-adjusted severe obesity increased from 7.7% to 9.7%. In self-reported 2025 data, every state and territory with available data had an obesity prevalence above 25% except the District of Columbia (24.2%). Among 13,888 U.S. adults followed for 115,797 person-years, obesity incidence was 28.1 per 1,000 person-years in 2001 to 2017, rose by 18% in 2013 to 2017 compared with 2009 to 2013, and was 62.1 per 1,000 person-years in adults with overweight compared with 8.8 in adults with normal weight. Projections estimate obesity in 48.9% and severe obesity in 24.2% of U.S. adults by 2030. Worldwide in 2024, 2.6 billion adults were overweight, including 940 million (about 16%) with obesity.

In an individual-participant data meta-analysis of prospective studies, hazard ratios for all-cause mortality were 1.45 for obesity grade 1, 1.94 for grade 2, and 2.76 for grade 3. In a population-based United Kingdom cohort, life expectancy from age 40 years was 4.2 years shorter in men and 3.5 years shorter in women with a BMI of 30 or greater than in those of healthy weight. The WHO estimates that higher-than-optimal BMI caused 3.7 million deaths in 2023. In Finnish cohorts and the UK Biobank, obesity was associated with 21 diseases, with confounder-adjusted hazard ratios compared with healthy weight of 2.83 for developing at least one obesity-related disease and 12.39 for complex multimorbidity. Obesity is associated with 13 types of cancer that account for more than 40% of annual cancer diagnoses.

Summary: humanistic and economic burden

Systematic reviews of reviews report that obesity is associated with lower generic and obesity-specific health-related quality of life (HRQoL) in all populations studied, with physical HRQoL declining as BMI rises and mental component scores reduced only in class III obesity; an update identified eight systematic reviews or meta-analyses published since 2017 with consistent findings and none on anti-obesity medications. In U.S. national survey data, the median SF-12 physical component score was 55.86 in respondents of normal weight and 47.21 in those with class 3 obesity, and the proportion reporting an inability to work rose from 10.3% to 26.9%. In the National Health and Wellness Survey of 69,742 adults, the largest declines in HRQoL were generally observed between class 2 and class 3 obesity. The ICER obesity model applies a utility reduction of 0.006 per one-unit increase in BMI, and the ICER report describes weight bias in health care settings as “discouraging people from seeking care”. In an analysis of the STEP 1 and STEP 2 trials, 51.8% and 39.6% of participants receiving semaglutide 2.4 mg reached the meaningful within-person change threshold for IWQOL-Lite-CT Physical Function at week 68, compared with 28.3% and 29.5% receiving placebo.

Using Medical Expenditure Panel Survey data for 175,726 respondents (2019 U.S. dollars), obesity was associated with $1,861 in excess annual medical costs per adult, or $172.74 billion nationally, and severe obesity with $3,097 per adult. An instrumental-variable analysis estimated annual medical costs $2,505 (100%) higher in adults with obesity than in adults of normal weight, rising from 68.4% higher for class 1 to 233.6% higher for class 3, $2,868 higher with public insurance and $2,058 higher with private insurance, and $260.6 billion in aggregate in 2016. Among 719,482 employees, employer costs for absenteeism, short-term disability, long-term disability, and workers’ compensation were $1,036, $611, $38, and $95 higher per year in the class 3 obesity cohort than in the normal weight cohort. A modeling study estimated that a 5% weight loss would reduce annual health care spending by $670 (8%) in adults with employer-sponsored insurance and by $1,262 (7%) in Medicare beneficiaries with 1 or more comorbid conditions, and a 25% weight loss by $2,849 (34%) and $5,442 (31%), respectively. Globally, the economic impact of overweight and obesity was estimated at 2.19% of gross domestic product in 2019, projected to rise to 3.29% by 2060.

VK2735 efficacy and safety

Summary: subcutaneous formulation

In the phase 2 VENTURE trial, 176 participants with obesity, or overweight with a weight-related comorbidity, and without diabetes were randomized to placebo or once-weekly subcutaneous VK2735 at 2.5, 5.0, 10, or 15 mg for 13 weeks. In the peer-reviewed publication, the least squares mean percent change in body weight from baseline to week 13 in the modified intent-to-treat population (mixed model for repeated measures) was −9.1% (2.5 mg), −10.9% (5.0 mg), −12.9% (10 mg), and −14.7% (15 mg), compared with −1.7% for placebo, with placebo-adjusted differences of −7.43 to −13.08 percentage points (p < 0.0001 for each dose). Weight reduction of at least 10% occurred in 40.1% to 89.1% of participants across the VK2735 arms and 3.0% with placebo; the topline press release reported 39% to 88% and 4%. The topline release reported no weight-loss plateau at week 13. Of 74 participants with prediabetes at baseline in the active arms, 58 (78%) were normoglycemic at week 13.

In the VENTURE safety population (175 participants), discontinuation of study drug due to a treatment-emergent adverse event occurred in 0 of 35 participants with placebo and in 1 (3%), 4 (11%), 4 (11%), and 7 (20%) of 35 participants at 2.5, 5.0, 10, and 15 mg. The most common drug-related events were nausea (36.6%), constipation (21.1%), and vomiting (12.6%), and gastrointestinal events were reported mainly early in treatment. Eight participants (4.6%) had 12 serious adverse events, 2 of which, in 1 participant, were considered drug-related; 1 death (head trauma from a fall) was assessed as unrelated. Mean heart rate increased by 3.3 to 9.3 bpm across the VK2735 arms and by 1.4 bpm with placebo, and anti-drug antibodies were detected in 9% to 23% of participants at week 13. No pancreatitis was reported.

In Part 1 of the phase 1 VK2735-102 maintenance study, reported in a press release, weight loss after 21 weeks of weekly dosing (15 to 22.5 mg) was 16.3% to 18.7% from baseline, compared with 0.1% for placebo. Over the following 12 weeks, participants switched to every-other-week dosing retained 83% to 97% of their week 21 weight loss and those switched to monthly dosing retained 82% to 90%, compared with 61% for participants switched to placebo. During induction, 22 of 166 VK2735-treated participants (13%) discontinued treatment early and 1 (1%) discontinued due to an adverse event. In the 28-day multiple ascending dose part of the phase 1 VK2735-101 study, mean body weight decreased by up to 7.8% from baseline (up to 6.0% relative to placebo); one serious adverse event (acute choledocholithiasis) occurred in a participant with a history of cholelithiasis.

Summary: oral formulation

In the phase 2 VENTURE-Oral Dosing trial, 280 participants were randomized to placebo, once-daily oral VK2735 at 15, 30, 60, 90, or 120 mg, or an exploratory cohort that received 90 mg and then 30 mg, for 13 weeks. Results are available in a topline press release, a congress poster, and company presentations; no peer-reviewed publication was identified. The least squares mean percent change in body weight at week 13 was −2.3%, −7.0%, −8.7%, −11.1%, and −12.2% at 15, 30, 60, 90, and 120 mg, compared with −1.3% for placebo (placebo-adjusted −1.0% to −10.9%); differences from placebo were statistically significant for doses above 15 mg. Weight loss of at least 10% occurred in 8% to 80% of participants across the dose arms and 5% with placebo. The exploratory cohort reached −9.2% at week 13 after transition from 90 mg to 30 mg.

Treatment discontinuation was 18% with placebo and 20% to 38% across the fixed-dose arms (38% at 120 mg), and discontinuation of treatment due to a treatment-emergent adverse event was 13% with placebo and 5% to 30% across the dose arms (30% at 120 mg). The release reported pooled rates of 28% for any treatment discontinuation and 20% for discontinuation due to an adverse event with VK2735. Nausea was reported in 58% of VK2735-treated participants and 48% with placebo, and vomiting in 26% and 10%; the company attributed discontinuations mainly to gastrointestinal adverse events and stated that the titration rate likely affected the gastrointestinal profile. The poster reported drug-related serious adverse events in 1 participant at 60 mg and in participants at 120 mg. Pharmacokinetic results from this trial have not been reported.

In the 28-day oral cohorts of the phase 1 VK2735-101 study (2.5 to 100 mg daily), mean body weight decreased by up to 8.2% from baseline (up to 6.8% relative to placebo). The congress poster reports 1 serious adverse event in the 60 mg cohort (1 of 9 participants), and an earlier interim release covering doses through 40 mg reported none.

Summary: ongoing phase 3 trials

Four phase 3 trials are underway, and none has reported results. The subcutaneous VANQUISH-1 and VANQUISH-2 trials are randomized, double-blind, placebo-controlled trials of once-weekly VK2735 7.5, 12.5, or 17.5 mg for 78 weeks. VANQUISH-1 enrolled adults without type 2 diabetes with obesity (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with at least one weight-related comorbidity; the November 2025 enrollment release reported approximately 4,650 participants, and later company documents report approximately 4,500. VANQUISH-2 enrolled approximately 1,000 adults with type 2 diabetes and obesity or overweight. The primary endpoint of each is the percent change in body weight from baseline compared with placebo after 78 weeks, and the company expects data in the second half of 2027.

The oral SUNRISE-1 and SUNRISE-2 trials are randomized, double-blind, placebo-controlled trials of once-daily oral VK2735 27.5, 35, or 55 mg for 68 weeks, each targeting 560 adults; SUNRISE-2 enrolls adults with type 2 diabetes. The company announced their initiation in October 2026, while the registry records listed both as “Not yet recruiting”. The company expects SUNRISE data in 2028.

Budget impact of VK2735

Summary: price, planned access channels, and comparator prices

No price, average sales price, or wholesale acquisition cost has been announced for either formulation of VK2735, and no cost-effectiveness analysis or budget impact model of VK2735 has been published. In 2026 investor conference transcripts, Viking Therapeutics described the obesity market as “50% of the business now is in cash”, stated that it is in discussions with direct-to-consumer companies, and said of that channel that “it's not through PBM, so there's no rebate wall”. The company stated that it “would expect to have access” to the Medicare GLP-1 Bridge program. In its Form 10-Q for the third quarter of 2026, the company stated that there would be “a much larger obesity market with reimbursement from third-party payors”.

Prices of the approved incretin-based comparators, as published in 2025 and 2026:

  • Semaglutide (Wegovy): wholesale acquisition cost of $1,349.02 for a 4-pen package of the 2.4 mg or the 7.2 mg injection and for a 30-tablet bottle of the 25 mg tablets, on the manufacturer's pricing page. The manufacturer announced a list price of $675 per month across Wegovy, Ozempic, and Rybelsus effective January 1, 2027, with no change to self-pay prices, and a price of $149 per month for the 1.5 mg starting dose of the tablets with savings offers.
  • Tirzepatide (Zepbound): a self-pay price “starting at $299” for all doses in the KwikPen or the single-dose vial through LillyDirect.
  • Orforglipron (Foundayo): self-pay price starting at $149 per month for the lowest dose; as little as $25 per month with the savings card for eligible commercially insured people; and $50 per month for eligible Medicare Part D individuals beginning as soon as July 1, 2026.
  • The American Diabetes Association 2026 Standards of Care list the average wholesale price and the National Average Drug Acquisition Cost for a 30-day supply as $1,619 and $1,303 for liraglutide 3 mg daily, $1,619 and $1,302 for semaglutide 2.4 mg once weekly, and $1,304 and $1,022 for tirzepatide.
Summary: class-level budget impact and cost-effectiveness

In its final evidence report of December 2025, ICER modeled injectable semaglutide, oral semaglutide, and tirzepatide, each added to lifestyle modification, in a lifetime Markov cohort model from the health sector perspective with 3% annual discounting. At annual net prices of $6,829 for injectable semaglutide and $7,973 for tirzepatide, with oral semaglutide assumed to cost the same as injectable semaglutide, the cost per QALY gained versus lifestyle modification was $57,779 for tirzepatide, $66,355 for injectable semaglutide, and $75,456 for oral semaglutide, and ICER estimated that no discount was needed to reach its health benefit price benchmarks. Over an undiscounted five-year horizon, ICER estimated about 92,000,000 eligible U.S. adults and a year-one budget impact per patient of $6,607 for injectable semaglutide and $7,711 for tirzepatide. Fewer than 1% of eligible people could be treated within five years without crossing ICER's $880 million annual threshold, including at the Medicare price of $245 per month.

Other U.S. analyses differ by price and perspective. ICER's prior assessment reported $237,000 per QALY gained for semaglutide at the net price then in effect. A peer-reviewed lifetime microsimulation reported $197,023 per QALY for tirzepatide and $467,676 per QALY for semaglutide, requiring discounts of 30.5% and 81.9% to reach $100,000 per QALY. A 30-year U.S. third-party payer model reported $23,556 to $144,296 per QALY gained for semaglutide 2.4 mg against its comparators, and a societal-perspective model estimated per-patient savings of $41,688 and 0.506 QALYs gained for tirzepatide versus semaglutide at maximum tolerated doses.

For Medicare, CBO estimated that authorizing coverage of anti-obesity medications would increase net federal spending by about $35 billion from 2026 to 2034, at a direct federal cost of roughly $5,600 per user in 2026. A published analysis estimated added annual Part D costs of $3.1 billion or $6.1 billion at 5% or 10% uptake among newly eligible patients. The CMS Medicare GLP-1 Bridge demonstration gives eligible Part D beneficiaries certain GLP-1 drugs for a $50 copay from July 1, 2026, to December 31, 2027, outside the Part D payment flow. In the KFF 2025 employer survey, 19% of firms with 200 or more workers covered GLP-1 agonists for weight loss. Obesity was associated with $1,861 in excess annual medical costs per adult (2019 dollars), and weight loss of 5% and 25% with estimated annual spending reductions of $670 and $2,849 among adults with employer-sponsored insurance.

Conclusions

Summary

VK2735 is an investigational dual GLP-1 and GIP receptor agonist developed by Viking Therapeutics as a once-weekly subcutaneous injection and a once-daily oral tablet for chronic weight management. Neither formulation is approved, and no new drug application has been submitted. The company expects data from the subcutaneous phase 3 VANQUISH trials in the second half of 2027 and from the oral phase 3 SUNRISE trials in 2028, and has given no price.

Obesity affected 40.3% of U.S. adults in 2021 to 2023, and was associated with $1,861 in excess annual medical costs per adult in 2019 dollars. Approved incretin-based comparators for chronic weight management include semaglutide (injection and tablet), tirzepatide (injection), and orforglipron (tablet).

The evidence for the subcutaneous formulation comprises one peer-reviewed phase 2 trial (VENTURE, 176 participants, 13 weeks), in which placebo-adjusted weight change at week 13 ranged from −7.43 to −13.08 percentage points across doses of 2.5 to 15 mg, and phase 1 studies reported in press releases and posters, including a maintenance study of every-other-week and monthly dosing after 21 weeks of weekly induction. The evidence for the oral formulation comprises one phase 2 trial (VENTURE-Oral Dosing, 280 participants, 13 weeks) reported in a press release, a congress poster, and company presentations, with placebo-adjusted weight change of −1.0% to −10.9% at doses of 15 to 120 mg, treatment discontinuation of 20% to 38% across dose arms compared with 18% for placebo, and a 28-day phase 1 study. In both formulations, gastrointestinal adverse events were the most common adverse events and the most common reason for discontinuing treatment.

The phase 2 trials lasted 13 weeks, excluded people with diabetes, and reported no weight-loss plateau at week 13, so the effect after the 1 year of treatment that FDA draft guidance uses as its efficacy benchmark is not known for either formulation. The oral phase 3 doses (27.5, 35, and 55 mg) were not studied as fixed-dose arms in phase 2. Efficacy and safety at the phase 3 doses and durations, in people with type 2 diabetes, and against an active comparator have not been reported for either formulation.